OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

2016328 citationsJournal Article

Authors

Victor W. Νitti · Urology Associates

Roger R. Dmochowski · Vanderbilt University

Sender Herschorn · University of Toronto

Peter K. Sand · University of Chicago

Catherine Thompson · Allergan (United Kingdom)

Christopher Nardo · Allergan (United States)

Xiaohong Yan ·

Abstract

OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated.

Topics & Keywords

Pelvic floor disorders treatments Urinary Bladder and Prostate Research Urinary Tract Infections Management

Publication Details

Published in: The Journal of Urology

Volume 197, Issue 2S, pp. S216-S223

DOI: 10.1016/j.juro.2016.10.109

Field-Weighted Citation Impact: 32.19

Command Palette

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Authors

Abstract

Topics & Keywords

Publication Details